Deciphering the role of vasopressin in primary aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 9, 2015, Pages 3297-3303

  Nogueira Silva, Luis ^a,b   Blanchard, Anne ^c,d,e   Curis, Emmanuel ^c,d,f   Lorthioir, Aurélien ^c,d   Zhygalina, Valentina ^c,d   Bergerot, Damien ^e   Baron, Stéphanie ^c,d   Amar, Laurence ^c,d   Bobrie, Guillaume ^d   Plouin, Pierre François ^c,d   Ménard, Joël ^c   Azizi, Michel ^c,d,e  

^a Universidade do Porto   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSERM   (France)

^f UMR S 1144   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; COPEPTIN; CREATININE; DIURETIC AGENT; GLUCOSE; POTASSIUM; SODIUM; VASOPRESSIN; ARGIPRESSIN; GLYCOPEPTIDE;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; ESSENTIAL HYPERTENSION; FEMALE; FREE WATER CLEARANCE; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; URINE OSMOLALITY; URINE VOLUME; VASCULAR RESISTANCE; BLOOD; HYPERALDOSTERONISM; HYPERTENSION; MIDDLE AGED; OSMOLARITY;

ADULT; AGED; ARGININE VASOPRESSIN; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOPEPTIDES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION;

EID: 84941703070     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/JC.2015-2007     Document Type: Article

References (34)

1. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study. Lancet. 2008;371:1921-1926.
2. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism:Anendocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93:3266-3281.
3. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
4. Beretta-Piccoli C, Davies DL, Brown JJ, et al. Relation of blood pressure with body and plasma electrolytes in Conn's syndrome. J Hypertens. 1983;1:197-205.
5. Williams ED, Boddy K,BrownJJ, et al. Body elemental composition, with particular reference to total and exchangeable sodium and potassium and total chlorine, in untreated and treated primary hyperaldosteronism. J Hypertens. 1984;2:171-176.
6. Kelly TM, Nelson DH. Sodium excretion and atrial natriuretic peptide levels during mineralocorticoid administration. A mechanism for the escape from hyperaldosteronism. Endocr Res. 1987;13:363-383.
7. Jia Z, Aoyagi T, Kohan DE, Yang T. mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol. 2010;299:F155-F166.
8. Crofton JT, Share L, Shade RE, Lee-Kwon WJ, Manning M, Sawyer WH. The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat. Hypertension. 1979; 1:31-38.
9. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol. 1979;236:F321-F332.
10. Gregoire JR. Adjustment of the osmostat in primary aldosteronism. Mayo Clin Proc. 1994;69:1108-1110.
11. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int. 1976;10:25-37.
12. Ando T, Shimamoto K, Nakahashi Y, et al. Plasma antidiuretic hormone levels in patients with normal and low renin essential hypertension, and secondary hypertension. Endocrinol Jpn. 1983;30: 567-570.
13. Kimura T, Yamamoto T, Ohta M, et al. Impaired vasopressin suppression and enhanced atrial natriuretic hormone release following an acute water load in primary aldosteronism. Eur J Endocrinol. 1997;137:154-161.
14. Blanchard A, Steichen O, De Mota N, et al. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure. J Clin Endocrinol Metab. 2013;98:2084-2089.
15. Gandhi PU, Januzzi JL Jr. Can copeptin emerge from the growing shadow of the troponins? Eur Heart J. 2015;36(6):333-336.
16. Jochberger S, Dörler J, Luckner G, et al. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med. 2009;37:476-482.
17. OsI, Kjeldsen SE, Skjøtø J, et al. Increased plasma vasopressin in low renin essential hypertension. Hypertension. 1986;8:506-513.
18. Timper K, Fenske W, Kuhn F, et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: A prospective multicenter study. J Clin Endocrinol Metab. 2015: jc20144507.
19. Urwyler SA, Schuetz P, Fluri F, et al. Prognostic value of copeptin: One-year outcome in patients with acute stroke. Stroke. 2010;41: 1564-1567.
20. Morgenthaler NG, Struck J, Alonso C, Bergmann. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112-119.
21. Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI. Changes of vasopressin in hypertension: Cause or effect? Lancet. 1976;1: 1255-1257.
22. Rutecki GW, Cox JW, Robertson GW, Francisco LL, Ferris TF. Urinary concentrating ability and antidiuretic hormone responsiveness in the potassium-depleted dog. J Lab Clin Med. 1982;100:53-60.
23. Marples D, Frøkiaer J, Dørup J, Knepper MA, Nielsen S. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest. 1996;97: 1960-1968.
24. Hasler U, Leroy V, Martin PY, Féraille E. Aquaporin-2 abundance in the renal collecting duct: New insights from cultured cell models. Am J Physiol Renal Physiol. 2009; 297:F10-F18.
25. Hasler U, Mordasini D, Bianchi M, Vandewalle A, Féraille E, Martin PY. Dual influence of aldosterone on AQP2 expression in cultured renal collecting duct principal cells. J Biol Chem. 2003;278: 21639-21648.
26. Baxter J, Perloff D, Hsueh W, Biglieri E. The endocrinology of hypertension. 2nd ed. New York: McGraw-Hill, 1987.
27. Gavras I. GH role of vasopressin in hypertensive disorders. JH L, Brenner BM, eds. New York: Raven press, 1995.
28. Jeffries WB, Wang Y, Pettinger WA. Enhanced vasopressin (V2-receptor)-induced sodium retention in mineralocorticoid hypertension. Am J Physiol. 1988;254:F739-F746.
29. Kunes J, Nedvdek J, Zicha J. Vasopressin and water distribution in rats with DOCA-salt hypertension. J Hypertens Suppl. 1989;7: S204-S205.
30. Thibonnier M, Aldigier JC, Soto ME, Sassano P, Menard J, Corvol P. Abnormalities and drug-induced alterations of vasopressin in human hypertension. Clin Sci (Lond). 1981;61(Suppl 7):149s-152s.
31. Gavras H. Role of vasopressin in clinical hypertension and congestive cardiac failure: Interaction with the sympathetic nervous system. Clin Chem. 1991;37:1828-1830.
32. Gavras H, Ribeiro AB, Kohlmann O, et al. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension. 1984;6:I156-I160.
33. Saravia FE, GrilloCA,FerriniM,et al. Changes of hypothalamic and plasma vasopressin in rats with deoxycorticosterone-acetate induced salt appetite. J Steroid Biochem Mol Biol. 1999;70:47-57.
34. Thibonnier M, Sassano P, Daufresne S, Corvol P, Menard J. Osmoregulation and renal effects of vasopressin in normal and mildly hypertensive subjects. Kidney Int. 1984;25:411-415.